Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich.
Author(s) -
H. Schuster,
G Rauh,
B. Kormann,
T Hepp,
Steve E. Humphries,
C. Keller,
G. Wolfram,
N. Zöllner
Publication year - 1990
Publication title -
arteriosclerosis an official journal of the american heart association inc
Language(s) - English
Resource type - Journals
eISSN - 2330-9180
pISSN - 0276-5047
DOI - 10.1161/01.atv.10.4.577
Subject(s) - apolipoprotein b , familial hypercholesterolemia , ldl receptor , glutamine , medicine , mutant , endocrinology , apolipoprotein e , arginine , proband , mutation , allele , lipoprotein , genetics , cholesterol , biology , gene , amino acid , disease
It has recently been suggested that a substitution of glutamine for arginine at residue 3500 of apolipoprotein (apo) B-100 causes familial defective apo B-100 (FDB), an autosomal, dominantly inherited disorder, which leads to increased serum cholesterol levels. From a sample of 243 patients from Munich with type IIa hyperlipoproteinemia (HL), we have identified eight individuals with the apo B-100 arginine(3500)----glutamine mutation. In a group of 57 subjects with defective low density lipoprotein receptor (LDLR), no mutant apo B alleles were detected. The frequency of FDB in patients with type IIa HL was estimated to be 3%. In the kindreds of three of the probands, 10 additional carriers of the apo B mutation were identified. Clinical and biochemical data reveal a striking similarity between patients with FDB and those with a defect in the LDLR gene. Our data support previous findings that FDB is a serious disorder causing premature atherosclerosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom